Note: This document contains side effect information about oteseconazole. Some dosage forms listed on this page may not apply to the brand name Vivjoa.
Applies to oteseconazole: oral capsule.
Serious side effects of Vivjoa
Along with its needed effects, oteseconazole (the active ingredient contained in Vivjoa) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.
Check with your doctor immediately if any of the following side effects occur while taking oteseconazole:
Less common
- Burning while urinating
- difficult or painful urination
- heavy non menstrual vaginal bleeding
- hot flush
- longer or heavier menstrual periods
Other side effects of Vivjoa
Some side effects of oteseconazole may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.
Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:
More common
- Headache, severe and throbbing
Less common
- Acid or sour stomach
- belching
- heartburn
- indigestion
- nausea
- stomach discomfort, upset, or pain
For Healthcare Professionals
Applies to oteseconazole: oral capsule.
General
The most frequent adverse reactions (incidence greater than 2%) among treated patients in clinical trials were headache (includes headache, migraines, sinus headaches) and nausea.[Ref]
Cardiovascular
Frequency reported as less than 2%: Hot flushes[Ref]
Gastrointestinal
Frequency reported as less than 2%: Dyspepsia[Ref]
Genitourinary
Frequency reported as less than 2%: Dysuria, menorrhagia (includes genital hemorrhage, menorrhagia; menometrorrhagia; uterine hemorrhage, vaginal hemorrhage) metrorrhagia; vulvovaginal irritation (includes vulvovaginal burning sensation, vulvovaginal discomfort, and vulvovaginal pain)[Ref]
Metabolic
Frequency reported as less than 2%: Increase in blood creatinine phosphokinase[Ref]
